Evidence map›Paper›PMID 38459200›Full record

ArticleInnere Medizin (Heidelberg, Germany)2024

[Combined immunosuppression with cyclosporin A, mycophenolate mofetil (MMF) and dexamethasone for activity control of recurrent secondary hemophagocytic lymphohistiocytosis (sHLH) with underlying systemic lupus erythematosus (SLE)].

Modar Saleh, Katja Hampel, Jens Gerth, Stefan Merkelbach, Astrid Monecke, Lars-Olof Mügge

Abstract readCase ReportsEnglish Abstract
PubMed Publisher
In one paragraph

Article in Innere Medizin (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Modar SalehKlinik für Hämatologie und Onkologie, Heinrich Braun Klinikum, Karl-Keil-Straße 35, 08060, Zwickau, Deutschland. Modar.Saleh@hbk-zwickau.de.
Katja HampelKlinik für Hämatologie und Onkologie, Heinrich Braun Klinikum, Karl-Keil-Straße 35, 08060, Zwickau, Deutschland.
Jens GerthKlinik für Nephrologie, Heinrich Braun Klinikum, Zwickau, Deutschland.
Stefan MerkelbachKlinik für Neurologie, Heinrich Braun Klinikum, Zwickau, Deutschland.
Astrid MoneckeInstitut für Pathologie, Universitätsklinikum Leipzig, Leipzig, Deutschland.
Lars-Olof MüggeKlinik für Hämatologie und Onkologie, Heinrich Braun Klinikum, Karl-Keil-Straße 35, 08060, Zwickau, Deutschland.
Klinikum Braunschweig · DEUniversity Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 42-year-old female patient was admitted to hospital due to acute neurological symptoms (dysarthria, disorientation). After exclusion of cerebral ischemia and hemorrhage an autoimmune encephalitis was diagnosed. Shortly before as an outpatient the suspicion of the presence of systemic lupus erythematosus (SLE) was voiced. The patient showed a constellation of high levels of inflammatory laboratory parameters and within a few days developed a severe pancytopenia. In the presence of all diagnostic criteria a secondary hemophagocytic lymphohistiocytosis (sHLH) was diagnosed and confirmed by a kidney biopsy during the course of the underlying SLE. The immunosuppressive treatment with etoposide and high-dose dexamethasone according to the HLH-94 protocol only showed temporary success. After 3 weeks of treatment with a protocol-conform dose reduction, under running treatment a new exacerbation of symptoms was confirmed. A renewed dose escalation of the drugs used did not lead to control of the symptoms. The inflammatory activity could only be sustainably controlled by the use of cyclosporin A in combination with mycophenolate mofetil (MMF) and dexamethasone. After stabilization of the condition of the patient, an outpatient follow-up care was possible.

Indexed as

CyclosporineDexamethasoneDrug Therapy, CombinationImmunosuppressive AgentsLupus Erythematosus, SystemicLymphohistiocytosis, HemophagocyticMycophenolic AcidAdultFemaleHumansRecurrenceCyclosporineDexamethasoneImmunosuppressive AgentsMycophenolic AcidCyclosporin AHemophagocytic lymphohistiocytosis (HLH)Mycophenolate mofetil (MMF)Systemic lupus erythematosus (SLE)

Identifiers

PMID38459200
OpenAlexW4392602657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.